文献速递妇科

TRIO-14:卡铂-紫杉醇联合加尼妥单抗一线治疗上皮性卵巢癌的II期随机对照试验

Results of TRIO-14, a phase II, multicenter, randomized, placebo-controlled trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-ganitumab in newly diagnosed epithelial ovarian cancer.
PubMed 文献 · Gynecol Oncol · 2021-10-09

TRIO-14是一项II期多中心随机安慰剂对照试验,纳入170例初治上皮性卵巢癌患者,比较卡铂/紫杉醇联合加尼妥单抗(IGF-1R单抗)与联合安慰剂的一线疗效。结果显示加尼妥单抗组中位无进展生存期(PFS)为15.7个月,安慰剂组为16.7个月(HR 1.23,95%CI 0.82-1.83,P=0.313),差异无统计学意义。加尼妥单抗组中性粒细胞减少、血小板减少和高血糖等不良事件及严重不良事件更常见,不支持在未选择患者中进一步研究。

要点

  • 加尼妥单抗联合化疗未改善初治上皮性卵巢癌的PFS。
  • 加尼妥单抗组血液学毒性和高血糖发生率更高,严重不良事件更多。
  • 探索性分析提示IGFBP2表达可能预测加尼妥单抗疗效。

核心结论

  • 在初治上皮性卵巢癌中,卡铂/紫杉醇联合加尼妥单抗 compared with 联合安慰剂未改善无进展生存期。
  • 结果不支持在未选择的EOC患者中进一步研究加尼妥单抗。

研究设计与样本

  • II期、多中心、随机、安慰剂对照试验(TRIO-14)。
  • 170例初治上皮性卵巢癌患者随机接受卡铂/紫杉醇联合加尼妥单抗(18 mg/kg q3w)或联合安慰剂6周期,后续6周期单药加尼妥单抗/安慰剂维持治疗。
  • 主要终点为无进展生存期,次要终点包括至进展时间和总生存期。

主要发现

  • 加尼妥单抗组中位PFS为15.7个月,安慰剂组为16.7个月(HR 1.23;95%CI 0.82-1.83,P=0.313)。
  • 加尼妥单抗组全部级别中性粒细胞减少(84.1% vs 71.4%)、血小板减少(75.3% vs 57.1%)和高血糖(15.9% vs 2.6%)更常见。
  • 加尼妥单抗组与药物相关的严重不良事件发生率为26.1%,安慰剂组为6.5%。
  • 加尼妥单抗组非进展相关致死事件更多(5例 vs 2例)。
  • 探索性模型显示IGFBP2表达可预测加尼妥单抗疗效(治疗交互作用;PFS,P=0.03;OS,P=0.01)。

临床怎么用

  • 不推荐在未选择的初治上皮性卵巢癌患者中加用加尼妥单抗。
  • IGFBP2表达可能作为未来生物标志物探索方向,但需进一步验证。

局限性

  • II期试验样本量有限(170例)。
  • 加尼妥单抗组剂量延迟更多,导致化疗相对剂量强度降低。
  • 生物标志物分析为探索性、回顾性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Insulin-like growth factor (IGF) signaling is implicated in pathogenesis and chemotherapy resistance of epithelial ovarian cancer (EOC). We explored efficacy and safety of adding ganitumab, a monoclonal antibody targeting IGF-1R, to carboplatin/paclitaxel (CP) chemotherapy in patients with primary EOC. DESIGN: Patients were randomly assigned to receive CP/ganitumab (18 mg/kg q3w) or CP/placebo for 6 cycles followed by 6 cycles of single agent ganitumab/placebo maintenance therapy as front-line therapy. Primary endpoint was progression free survival. Secondary endpoints were time to progression and overall survival. Pretreatment samples were prospectively collected for retrospective biomarker analyses. RESULTS: 170 patients enrolled. 165 patients assessable for toxicity. Median PFS was 15.7 months with CP/ganitumab and 16.7 months with CP/placebo (HR 1.23; 95% CI 0.82-1.83, P = 0.313). All grade neutropenia (84.1% vs 71.4%), thrombocytopenia (75.3% vs 57.1%) and hyperglycemia (15.9% vs 2.6%) were more common in the ganitumab group compared to the placebo group. Ganitumab/placebo related serious adverse events were reported in 26.1% of the patients with ganitumab and in 6.5% with placebo. Non-progression related fatal events were more common with ganitumab (5 versus 2 patients). The ganitumab group experienced more dose delays which resulted in lower relative dose intensity of chemotherapy in the experimental group. In an exploratory model IGFBP2 expression was predictive of ganitumab response (treatment interaction; PFS, P = 0.03; OS, P = 0.01). CONCLUSION: Addition of ganitumab to CP chemotherapy in primary EOC did not improve PFS. Our results do not support further study of ganitumab in unselected EOC patients.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Konecny GE, Hendrickson AEW, Davidson TM, et al. Results of TRIO-14, a phase II, multicenter, randomized, placebo-controlled trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-ganitumab in newly diagnosed epithelial ovarian cancer. Gynecol Oncol. 2021. PMID: 34642026. doi:10.1016/j.ygyno.2021.09.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。